Mitogen-Activated Protein Kinase Kinases
"Mitogen-Activated Protein Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine-threonine protein kinase family whose members are components in protein kinase cascades activated by diverse stimuli. These MAPK kinases phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES and are themselves phosphorylated by MAP KINASE KINASE KINASES. JNK kinases (also known as SAPK kinases) are a subfamily.
| Descriptor ID |
D020929
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565 D08.811.913.696.620.682.725.200 D12.644.360.440 D12.776.476.440
|
| Concept/Terms |
Mitogen-Activated Protein Kinase Kinases- Mitogen-Activated Protein Kinase Kinases
- Mitogen Activated Protein Kinase Kinases
- MAPKK
- MAPKKs
- MAP Kinase Kinases
- Kinase Kinases, MAP
- Kinases, MAP Kinase
- MAPK Kinases
- Kinases, MAPK
- Map Kinase Kinase
- Kinase Kinase, Map
- Kinase, Map Kinase
MAPK-ERK Kinases- MAPK-ERK Kinases
- Kinases, MAPK-ERK
- MAPK ERK Kinases
- MEKs
- MAP-ERK Kinase
- Kinase, MAP-ERK
- MAP ERK Kinase
|
Below are MeSH descriptors whose meaning is more general than "Mitogen-Activated Protein Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "Mitogen-Activated Protein Kinase Kinases".
This graph shows the total number of publications written about "Mitogen-Activated Protein Kinase Kinases" by people in this website by year, and whether "Mitogen-Activated Protein Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1999 | 3 | 1 | 4 |
| 2000 | 2 | 3 | 5 |
| 2001 | 0 | 1 | 1 |
| 2002 | 3 | 2 | 5 |
| 2003 | 2 | 2 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 3 | 1 | 4 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 3 | 4 |
| 2012 | 2 | 2 | 4 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 2 | 4 | 6 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mitogen-Activated Protein Kinase Kinases" by people in Profiles.
-
BRAF and MEK inhibitor-associated optic neuropathy in stage IIIC BRAF+ melanoma. Can J Ophthalmol. 2023 12; 58(6):e251-e253.
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
-
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
-
Combined MEK and JAK/STAT3 pathway inhibition effectively decreases SHH medulloblastoma tumor progression. Commun Biol. 2022 07 14; 5(1):697.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.
-
Clinical impact of selumetinib on pediatric elephantiasis neuromatosa. Pediatr Dermatol. 2022 Sep; 39(5):764-766.
-
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
-
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
-
Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome. PLoS Genet. 2021 12; 17(12):e1009971.
-
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma. Oncoimmunology. 2021; 10(1):1992880.